tiprankstipranks
Advertisement
Advertisement
Biomea Fusion options imply 22.0% move in share price post-earnings
PremiumThe FlyBiomea Fusion options imply 22.0% move in share price post-earnings
28d ago
Biomea Fusion Reports Positive Phase 2 T1D Trial Results
Premium
Company Announcements
Biomea Fusion Reports Positive Phase 2 T1D Trial Results
1M ago
Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial
Premium
The Fly
Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial
1M ago
Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes
PremiumThe FlyBiomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes
3M ago
Biomea Fusion management to meet virtually with Craig-Hallum
Premium
The Fly
Biomea Fusion management to meet virtually with Craig-Hallum
3M ago
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
Premium
Company Announcements
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
3M ago
Biomea Fusion presents COVALENT-111 study results at WCIRDC
PremiumThe FlyBiomea Fusion presents COVALENT-111 study results at WCIRDC
6M ago
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan
Premium
The Fly
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan
7M ago
Biomea Fusion price target lowered to $6 from $7 at Citi
Premium
The Fly
Biomea Fusion price target lowered to $6 from $7 at Citi
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100